Sinticabiotech
Synthica Biotech develops peptidomimetic drugs, like SNT001, that target a novel pharmacological pathway to induce apoptosis in melanoma cells. Their therapies aim to provide effective treatment options for this aggressive form of skin cancer.
Traction –/10
HQ unknown
- Biotechnology
Updated 5 months ago
Funding
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Synthica Biotech develops peptidomimetic drugs, like SNT001, that target a novel pharmacological pathway to induce apoptosis in melanoma cells. Their therapies aim to provide effective treatment options for this aggressive form of skin cancer.